[Ip-health] Infojustice Roundup – October 17, 2016

Michael Palmedo mpalmedo at wcl.american.edu
Mon Oct 17 12:10:14 PDT 2016


Infojustice Roundup



[snip]



TRIPS-Plus, Public Health and Performance-Based Rewards Schemes Options and Supplements for Policy Formation in Developing and Least Developed Countries



[Mohammed El-Said] The debate surrounding the creation of a balanced patent protection regime in countries is not new. For decades, policy makers experimented with the levels of protection. For example, the Netherlands abolished patents in the field of chemistry for decades between 1869 and 1910, in order to catch up with other European countries such as Germany. Similarly, between 1960 and 1980 a number of Asian economies—often referred to as the Tiger economies—adopted a systematic national policy of reverse engineering and imitation. Click here for more.<http://infojustice.org/archives/37104>



[snip]



An Open Letter to the Sixteen Governments Negotiating the Regional Comprehensive Economic Partnership (RCEP)



[Joint letter signed by 95 health, community and development organisations in the Asia Pacific region] ... The RCEP includes an intellectual property (IP) chapter with measures that threaten access to life saving essential medicines. Even though it does not include the United States, many of the provisions appear to have been borrowed from the US-Korea free trade agreement and the Trans Pacific Partnership agreement. Click here for more.<http://infojustice.org/archives/37192>


See also: See also: Open letter to the Ambassadors of RCEP-Negotiating Countries from the Delhi Network of Positive People. Link<https://donttradeourlivesaway.wordpress.com/2016/10/13/open-letter-to-ambassadors-in-india-of-rcep-negotiating-countries-by-delhi-network-of-positive-people/>.



55 Civil Society Organizations Ask US Government to Allow Export of Affordable Version of Expensive Prostate Cancer Drug Xtandi



[Zach Struver] Today, over 50 patient, senior citizen, global health, development, social justice, and faith groups urged the United States Government to use its rights to protect public health and accept the request by a Canadian generic drug manufacturer (Biolyse Pharma) to enter into an agreement to manufacture and export an affordable version of the taxpayer-funded prostate cancer drug enzalutamide to South Africa and other countries with low per-capita incomes relative to the United States. Click here for the full post on keionline.org.<http://keionline.org/node/2645>



[snip]



Indian Generic Firms Capturing Larger Share of U.S. Drug Imports



[Mike Palmedo] India is often called the “pharmacy of the developing world” because its pharmaceutical firms provide a large portion of the generic drugs consumed in the South. However, Northern countries are increasingly importing Indian drugs as well, as high prices have led to greater generic uptake. As an example, the United States has greatly expanded the amount of medicines it buys from India. UN Comtrade data shows that last year, 20% of U.S. pharmaceutical imports by quantity came from India, up from a negligible 0.002% in 1996. Click here for more.<http://infojustice.org/archives/37179>



How Big Pharma’s Shadow Regulation Censors the Internet



[Jeremy Malcolm] Americans pay by far the highest prices in the world for most prescription drugs, and of course big pharma would like to keep it that way. Key measures that the industry relies upon in this regard are the Prescription Drug Marketing Act [PDF] and Ryan Haight Online Pharmacy Consumer Protection Act [PDF], which make it unlawful for most Americans to access lower-priced drugs from overseas, coupled with the powers of U.S. Customs and Border Protection (CBP) to seize such drugs at the border on their own initiative. Click here for more.<http://infojustice.org/archives/37098>



[snip]






More information about the Ip-health mailing list